New partners hope to identify targeting peptides for RNAi drugs


Orbit Discovery and start-up SanegeneBio have entered into a Master Service Agreement to identify tissue-specific delivery of a wide range of RNA therapeutics. 

The agreement covers activities ranging from hit ID to cell-based internalisation studies, with an option for Sanegene to further develop the hits resulting from the screening activities. 

Orbit’s technology enables the screening of large libraries of peptides using a combination of DNA encoded libraries and bead-based presentation. The peptide display engine addresses soluble targets and targets in situ, both on and in cells. 

Dr Neil Butt, Chief Executive Officer of Orbit Discovery, commented: “Sanegene has established an incredible ability to screen for RNAi molecules in a robust and efficient manner. 

“Our aim is to make screening more relevant to the final biological read-outs, to ensure the right leads are selected first time, every time. This has the end goal of enabling the generation of future therapeutics with low toxicity and tissue specificity and ultimately, safer and more effective medicines.” 


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free